Study: Xience V outperforms bare-metal, first-generation stents

06/17/2009 | Forbes

In a six-month follow-up study, Dutch cardiologists found that patients who received Abbott Vascular's Xience V everolimus-eluting stent were less likely to die or experience heart attacks or artery blockage than those who received bare-metal stents or first-generation drug-coated stents. Although the findings are "reassuring," large-scale studies on the device are still needed, an interventional cardiologist said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA